详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Abdominal Oncology, Cancer Center, West China Hospital, Chengdu, Sichuan, China [2]Department of Chemotherapy, Sichuan Cancer Hospital, Chengdu, Sichuan, China

出处：

DOI：

ISSN：

关键词： chemosensitivity platinum drug resistance colon cancer

摘要：

Purpose: Lobaplatin, heptaplatin, and dicycloplatin are three new platinum drugs. The aim of this study is to investigate the chemosensitivity of resistant colon cancer cell lines to these three drugs. Methods: Eight resistant colon cancer cell lines (four oxaliplatin-resistant colon cancer cell lines and four irinotecan-resistant colon cancer cell lines) were cultured in 96-well plates. Lobaplatin, heptaplatin, and dicycloplatin were added in various concentrations. IC50 was determined by MTT assay and the results were confirmed by CCK-8 assay. A cell death detection ELISA assay was performed to quantitate the apoptotic index by detecting the histone-associated DNA fragments generated by the apoptotic cells. Results: Lobaplatin and heptaplatin had an inhibiting effect in all resistant cell lines, dicycloplatin demonstrate only weak antitumor activity in vitro. Conclusions: We confirmed the efficacy of two platinum drugs to oxaliplatin/irinotecan-resistant colon cancer cell lines, suggesting these two drugs could be considered for improving the control of recurrent colon cancer following initial therapy with oxaliplatin and irinotecan.

基金：

基金编号： 30672378

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2014]版：

大类 | 4 区医学

小类 | 4 区药学

最新[2023]版：

大类 | 4 区医学

小类 | 4 区药学

JCR分区：

出版当年[2014]版：

Q4 PHARMACOLOGY & PHARMACY

最新[2023]版：

Q4 PHARMACOLOGY & PHARMACY

影响因子： 0.9 最新[2023版] 0.9 最新五年平均 1.223 出版当年[2014版] 1.166 出版当年五年平均 1.044 出版前一年[2013版] 1.129 出版后一年[2015版]

第一作者：

第一作者机构： [1]Department of Abdominal Oncology, Cancer Center, West China Hospital, Chengdu, Sichuan, China [2]Department of Chemotherapy, Sichuan Cancer Hospital, Chengdu, Sichuan, China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat [2]氢质子磁共振频谱活体检测结肠癌耐药性的初步探讨 [3]Nanomedicine Combats Drug Resistance in Lung Cancer [4]Managing Cancer Drug Resistance from the Perspective of Inflammation [5]Editorial: Non-genetic adaptive drug resistance in cancer [6]Protein degradation: expanding the toolbox to restrain cancer drug resistance [7]Combining kinase inhibitors for optimally co-targeting cancer and drug escape by exploitation of drug target promiscuities. [8]Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway. [9]Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. [10]ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma.